Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sure are a lot of folks who sold too early. Bummer!
I think we'll be seeing a hot RSI running for awhile. New e-mails out, Frankfurt up over 40%, massive demand. Any pullbacks will be slight and short-lived.
Smoke 'em if you got 'em, folks.
Today is going to be very, very good. Looks like a $.40 break any time now! Wow!!
NEW E-mail OUT! We have a long way to any dump!! It's all run, run, run -- IMO.
"The stars have finally aligned for TAGG and it is soaring every day in a never-before-seen fashion. For members still sitting on the sideline WAKE UP! Jumping on TAGG now before it soars past $1.00 could be the best move you can make.
While you may not be able to secure gains as big as our astute members who bought TAGG in the 10 cent range there is still a lot of upside left.
What is fueling this phenomenal run? Many factors are in play:
1. Rumors of a Microsoft buy out are swirling around.
2. There is a very strong short squeeze happening as we speak as market makers are having to buy back millions of shares in the open market.
3. Overseas investors are buying an unprecedented amount of shares of TAGG
4. Microsoft just released its new Windows 8 system and Surface tablets (this could be directly related to the rumors of a MS buy out)
As you know Microsoft has totally revamped its image with Windows 8 and its new tablets. Things are 100% new now and Microsoft is a hip company again. With the new launch of their operating system Microsoft hopes to become extremely relevant in the tech world again and take on Apple and Google head first.
TagLikeMe is a natural target for Microsoft but it was also mentioned earlier that Facebook could be looking at acquiring TagLikeMe. Sounds confusing?
It shouldn't be because we have to keep in mind that Microsoft owns a sizable portion of Facebook. So these 2 rumors may be interrelated somehow.
One more important fact to keep in mind is that TagLikeMe has developed software to run on Microsoft's news Windows 8 platform which is expected to be launched today (at the same time as Windows 8)
Either way should a buy out occur by either one of these giants we will reap a hefty reward."
Everyone pretty much knows how it works with certain posters! LOL
This is going to run and run hard. We won't be seeing any significant downward pressure for quite some time.
APS looks to want to run this to $1 and beyond. We have a long, long, long run ahead of us!
Enjoy the ride up everyone!!!!
This ran EOD just like it's been doing the last few days...and that has always resulted in a next morning gap. Will it happen again?? We'll find out tomorrow morning, but my guess is 'yes'!
What if news hits tonight?
What if news hits tomorrow morning?
TAGG has been pretty consistent at releasing news that does the PPS good. Buying demand is still strong and seems to be getting even stronger. It's still a penny stock, but moving more into the territory of traders who won't touch stocks under a quarter ($.25 that is).
All signs point to a continued run, with no significant pullback for quite some time yet.
APS has much to make up for and I think this one will make many who are in forget about the last one!
It was another fun day, watching this one move up so rapidly, but yet pausing to consolidate. Ready for the next leg up of profits!
Good luck to all!
Wow, we just cut through $.30s like butter, baby!
Hanging on very tightly now, and will be buying on dips, big time! Come on check, CLEAR!!!
Wooo Hooo!!!!!!!!!!!! $.30!!!!!
Break out and run!!
Just like clockwork...power hour, run into the close and gappa in the morning!
Awesome!!!!!
And to think, I nearly sold a couple days ago! Good think common sense got the better of me!
Still waiting to buy more next week when funds arrive. I hope to see a pullback when I do, but the shares I currently own are happy not to!
Go TAGG!
All I know is I mobilized some cash and I am having trouble buying -- every time I try, the PPS keeps increasing on me! That only happens with serious buying pressure. TAGG hasn't seen it's best days yet, IMO.
I predict another afternoon new HOD, like the last few days.
And another possible gapper in the morning??? Like the last few days.
Demand is strong here. Outlook is very good.
New e-mails just out. "TAGG could jump to 40 cents today!"
Wow is right! And we haven't seen anything yet, IMO. This has so much more room to run!!! Dang, I wish I had more available cash. Have a wait a few days for that! But if it's still under a buck, I'll be buying more!!!
Go TAGG!!!!!
Just like the last few days. It will run into the close, then gap up in the morning!
I agree with everyone who states that this will run to .50 and beyond. Too much potential here for big gains, not to play, if only just a little wager. IMO
Me too. In before I knew it was APS that is. After they announced, it was just more confirmation -- as they have much to make up for!
We are kissing another HOD, nearly there. If it should break .21, it will fly IMO. And it will jump cents at a time, most likely, as predicted.
Just a little turbulence folks, nothing to worry about! ;) :D
TAGG mentioned in Top 5 Stocks today.
"Tag Like Me Corp (TAGG) was having a strong day on the volume front and also trading higher. TAGG was up by 3% on $1.8 million traded just in the first hour on Wall Street today."
New e-mail out: "TAGG is strap to a rocket..."
Probably what has fueled this 2:30 run.
Perhaps you should take a look.
SYN is a whole different company, under completely new management, funded and backed by RJ Kirk.
If that name doesn't tickle your biotech-money-making bone, nothing will. IMO
When Kirk bought in, I bought more. And right now, I'm up nicely.
Their pipeline is brimming, with Trimesta alone being blockbuster enough to make multiples of the current PPS. But there's more, so much more, so many different revenue streams.
It's a wait, but when it all comes to fruition, or even *some* of it, investors will be quite pleased.
TAGG is really holding strong here today. Not much by way of any dips, thus far. There is a ton of buying interest and that is pushing up the PPS.
This could run strong EOD, like it has the last two days. I have considered selling at the end of each of the previous two days, but thankfully held off. I'm up so much more now than I would have been!
I don't think we've even seen the tip of this iceberg yet.
GLTA
Congratulations Mr. Wowza! Nice gain.
I'm still holding, as I expect more will be forthcoming.
Up another 10% so far today! Can't beat that. TAGG has been a consistent performer, with plenty of room for flips.
It would appear the intent is to continue to take it up from here.
.20 is a given BEFORE EOD, IMO.
Looking more like .25 or so!
Mid-morning update e-mail:
"Hi Everyone,
This is an urgent update for you to keep TAGG on your radar.
Our #1 pick has already traded over 13 million shares and is about to explode. This is the time where TAGG could start going parabolic and jump 4-5 cents at a time!
We want all our members to consider TAGG once again at these levels before it is too late. Because the next time you look it could be trading at 25 cents or more...."
Parabolic is good. :)
As predicted, the run continues today. Some real coin possible here folks!
Good luck everyone!
Settling of day trades. There is no AH for TAGG. It's all good.
Gap in the morning? .16 or .17 perhaps?
Agree because it's running so hard, EOD. Tomorrow it should continue to run.
Yowza, what's going on with TAGG today? Is there news or something? I've been away all day and was surprised to see it so nicely up and obviously rising -- esp. for a Friday!
TDA often has trading issues. There is no DTC chill on ICPA. That's complete fallacy. Complete. Fallacy.
Yep, that's what I'm thinking, gap will fill then it will run.
TAGG has been a great swing play -- but one I think will take off for bigger pastures pretty soon. IMO
Longs are definitely scooping up shares as funds are available!! I now own more shares than ever! I never thought I would be picking them up at these prices, but as luck would have it, I am. Naysayers do have their purpose. :)
Patience here folks. Longs WILL BE rewarded. Still long and strong here -- even though I don't post much anymore. Real longs often chat elsewhere.
Looking forward to seeing future Qs, when Clearvision rolls out and ICPA starts rolling in it's share as well.
GLTAL
Go ICPA!!!
SYN has an amazing pipeline and news out today!
Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
-- Acinetobacter Infections Pose Growing Concern in Hospitals, and in Military and Natural Disaster Trauma Centers --
-- Company Engages Former Pfizer/Wyeth Global Infectious Disease Pharmaceutical Executive to Provide Expertise on Advancing Infectious Disease Pipeline --
ANN ARBOR, Mich., Sept. 18, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, today announced that it has initiated efforts to develop a monoclonal antibody (mAb) therapy for the treatment of acinetobacter infections. Many strains of Acinetobacter are multidrug-resistant and pose an increasing global threat to hospitalized patients, wounded military personnel and those affected by natural disasters. The Company also announced that it has engaged Lewis (Lew) Barrett, former Assistant Vice President, Established Products at Pfizer and Vice President Global Business Manager, Infectious Diseases at Wyeth Pharmaceuticals, to bring his expertise in the development, commercialization and launch of infectious disease product candidates to the Synthetic Biologics' team.
Acinetobacter is a difficult to treat pathogen due to its rapid and well-established resistance to most antibiotics, making it a multidrug-resistant pathogen[1]. In addition, as a biofilm-forming pathogen, Acinetobacter has the ability to survive up to twice as long as non-biofilm-forming pathogens[2]. In the U.S., Acinetobacter has been reported to be the cause of up to 2.6% of hospital acquired infections, 1.3% of bloodstream infections and 7% of ICU respiratory tract infections[3], and more than half of the Acinetobacter isolates are multidrug-resistant[4]. Patients with infections caused by Acinetobacter have been reported having mortality rates ranging from 7.8% to 43% in the hospital and in the ICU[5]. While Acinetobacter is a well-documented pathogen in the hospital setting, this pathogen also poses an increasing danger to wounded servicemen and women in military treatment centers[6] and to those treated in trauma centers fo llowing natural disasters[7].
The initiation of mAb development for the treatment of acinetobacter infection is the first of the three initial targeted infectious diseases the Company intends to pursue as part of its most recent collaboration with Intrexon Corporation. In August 2012, Synthetic Biologics entered into a worldwide exclusive channel collaboration with Intrexon Corporation for the development and commercialization of mAb therapies to treat certain infectious diseases not adequately addressed by existing therapies. Under this collaboration, the Company intends to utilize Intrexon's comprehensive suite of proprietary technologies, including the mAbLogix™ and LEAP™ platforms, to develop fully human mAbs to specifically and rapidly neutralize/clear acinetobacter pathogens. The collaboration may optionally be expanded to include up to an additional five infectious disease indications.
"We are pleased to begin work on a mAb therapy to treat acinetobacter infections. Acinetobacter has developed an increased resistance to antibiotics and other drugs over time, and a new therapeutic option is needed to treat infectious diseases caused by this bacteria," said Jeffrey Riley, Chief Executive Officer of Synthetic Biologics, Inc. "Our collaboration with Intrexon provides access to state-of-the-art platforms that have tremendous potential to produce a broad spectrum of fully human antibodies to fight against Acinetobacter where other options have failed."
Mr. Riley concluded, "We welcome Lew Barrett to our team and look forward to benefiting from his many years of experience around the development and commercialization of anti-infectives, as we develop mAbs for the treatment of acinetobacter infections. We also look forward to disclosing additional infectious disease indications we intend to pursue in the near future."
During his 25-year career at Wyeth (acquired by Pfizer in 2009), Mr. Barrett successfully led, co-chaired or served as the senior marketing executive on teams that focused on infectious diseases, oncology, transplantation, and hemophilia. He brings to Synthetic Biologics his expertise in U.S. and global strategy, domestic/global branding, clinical development, medical affairs, supply chain, business development and strategic alliance management. He built the brand and led global commercialization efforts for Wyeth's in-line IV antibiotic, Zosyn®/Tazocin® (the second IV antibiotic to achieve $1 billion+ in sales), and managed the U.S. launch of Wyeth's broad-spectrum IV antibiotic, Tygacil®. In 2010, Mr. Barrett formed LL Barrett Biopharmaceutical Consulting, LLC, and utilizing his depth of experience in the anti-infective, hospital and biopharma fields, provides strategic consultation to the global life sciences field with a particular focus on brand strategy, lifecycle st rategy, business development, and strategic communications.
"Acinetobacter has consistently demonstrated its ability to rapidly develop resistance to antibiotics. We believe the threat of this pathogen coupled with a scarcity of new antibiotics creates a perfect storm. Novel biologic therapies such as Synthetic Biologics' mAbs, with new targets and mechanisms, are especially exciting," stated Mr. Barrett. "I look forward to working with the Company as they work toward developing new therapeutic candidates for a field of medicine where the availability of effective interventions has declined."
About Monoclonal Antibodies (mAbs)
Acting as the body's army, antibodies are proteins, generally found in the bloodstream, that provide immunity in detecting and destroying pathogens, such as viruses and bacteria and their associated toxins. MAbs can also be designed and produced as therapeutic agents, utilizing protein engineering and recombinant production technologies. The mAbs being developed under the Synthetic Biologics' collaboration with Intrexon are intended to supplement a patient's own immune system by providing the means to specifically and rapidly neutralize and/or clear specific pathogens and toxins of interest in a process known as "passive immunity". Many pathogens that cause infectious diseases are innately resistant to, or over time have developed increased resistance to, antibiotics and other drugs. Synthetic Biologics intends to utilize Intrexon's comprehensive suite of proprietary mAb design and recombinant protein production technologies to efficiently create potent candidate mAbs for human testing and use to specifically treat certain infectious diseases for which current therapies are unavailable or inadequate.
About Synthetic Biologics, Inc.
Synthetic Biologics is a biotechnology company focused on the development of product candidates to address serious diseases and unmet medical needs. Synthetic Biologics is developing the following synthetic biologic candidates: a series of monoclonal antibodies (mAbs) for the treatment of serious infectious diseases not adequately addressed by existing therapies and a synthetic DNA-based therapy for the treatment of pulmonary arterial hypertension (PAH). The Company is also developing drug candidates for the treatment of relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, amyotrophic lateral sclerosis (ALS) and fibromyalgia (partnered with Meda AB). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.
mAbLogix™ and LEAP™ are registered trademarks of Intrexon Corporation.
Zosyn®, Tazocin® and Tygacil® are registered trademarks of Pfizer or its affiliates.
Ruh roh. Looks like someone is trying to nudge the sleeping giant....
SYN is the biggest sleeper stock there is. So much going on but the market is generally unaware. A little awareness and realization of the incredible pipeline that has been building and...
skidoosh!!
:)
GLTAL
Let's have a really good day!
None whatsoever. Yhoo has been very, very screwy lately with SYN. No institutional ownership. Disappearing and reappearing message board. If I was a conspiracy theorist....
hey wait, I AM! LOL
It all spells good things in my mind, but the process of getting there is going to be a little shaky (apparently)!
GO SYN!!!
I am just waiting for a break above $3 as my first big happy dance, on the way to $5+. :)
You are right about this -- it's all about the revenues, which to me is very exciting and makes ICPA different from other pennies. It's in a whole separate category - one where it is considered a real company with real products and services and real growth potential. Not some mining on Mars POS that flies on the herd mentality and sinks twice as quickly! Naysayers aren't given much to work with when time after time what Steve says will happen happens!
Q after Q after Q we will see revenues begin to pile up. Growth potential is the name of the game -- and ICPA is about to go hyperbolic on growth!
IMVEO, of course!
Go ICPA!
SYN needs tangible good news and more volume.
Low float will make this thing really fly, when it does.
We've seen it before...but it seems the float is locking up even tighter. Most are not flipping at this point (can't really!!), but waiting for something good to precipitate from the Intrexon collaboration. Or Effirma. Or Trimesta. Or all of the above.
Remember, we hit $2.50 not very many weeks ago. We'll be back there and beyond again, IMO.
ICPA ready for a big bounce, IMO.
No, we weren't. No one ever here said the Q2 would be anything but neutral. What we said was that beginning in Q3 or Q4 and subsequent quarters, as revenues started rolling in, ICPA would be looking fine. I still believe this, based upon what we know of the deals that have been done and when they will launch.
I am still holding ALL my shares and am apparently lucky enough to be able to load more at these levels. It's insane!!! But, I'll take it. I'm looking very forward to Q3, Q4 and beyond.
Some of us do still know what we own - even if others can't see it.
Go ICPA!!!
Yes, Perchy, uplisting will be HUGE for ICPA.
However, I would exercise a little caution of the 30-40 day timeframe. Yes, it could happen within the timeframe, from the day it was mentioned. But it is unclear if the countdown starts there. Maybe it is 30-40 days from 'application'? Or 30-40 days from 'approval'? We don't really know.
Bottom line is, it'll happen when it happens if it happens. Just another iron in the fire to look forward too. There are so many, it's hard to keep count. Confirmation of ALL of them is forthcoming. True Honey Badgers know this and will wait (buying more as they can and as opportunities arise).
Everyone knows in the world of equities only 2 days matter -- the day you buy and the day you sell.
Good luck to all longs...we STILL know what we own!!!
Go ICPA!
Ha! I'm usually around, always investing in ICPA, but enjoying the summertime as well.
In a few weeks, we'll be back to more serious market time!
Right around the corner.... http://clearvisiondigitalnetworks.com/content/entertainment/
Nice logo there!!! Offical PR should be out any time.
GLTAL
Couldn't agree more!!
Uplisting (in the works) will be HUGE for ICPA. It will open up a whole new world of investors and lessen the flipper mentality that has been messing with this company.
If some people can't see where this company is going, and what it's doing to build up to that point, that's their problem.
Those of us who do see will be the ones benefitting down the road.
IMO
Go ICPA!!!
Looks like a further collaboration with Intrexon is going on!!!
http://www.genengnews.com/gen-news-highlights/synthetic-biology-firms-ally-on-infectious-disease-mabs/81247154/
Moving right along! The market should respond positively to this, perhaps after the conference call clarifies things a bit more.
We all knew *something* was up!!
Go SYN!
Hahaaha, yeah we know 'the truth' can only be counted on by anonymous message board posters!
So tell me, when did Samblis state anything that did not occur? I don't think you can/should lump him in with other pinkie CEOs as you call them.
ICPA is not a pink anyway. They are OTC -- soon to be potentially uplisting to QX.
So again, stick to the facts please. When has he misled shareholders? Specifics.
Shareholders have been told by the CEO of ICPA that Punch has received commitments totalling approx. $10-15 million annually (Sept. to Sept.). So I am pretty sure it doesn't matter what other folks believe that might contradict what the CEO states.
Shareholders should only deal with the facts and the facts have been stated by the CEO who has thus far proven himself to be 100% trustworthy. Anyone who does their DD on ICPA knows this. Other speculations against those facts are meritless.
Go ICPA!!!